Zusammenfassung der Ressource
Cancer Biomarkers
- INTRO
- Biomarker definition
- bioimarkers can be described as measurable and quantifiable
biological indicators of normal physiological function, disease
states, or of the body's response to therapeutics.
- Biomarkers are present in bodily fluids, such as blood
and blood fractions (plasma, serum etc), urine, saliva
and tissues.
- Biomarkers, while often considered to only be proteins, can also take the
form of a specific measurement such as an ECG or imaging test (E.g. MRI or
CT scan) or can be a physical assessment or verbal test
- The Biomarkers Definitions Working Group (2001) classified the
different types of biomarker based on function
- Biomarkers can be
- Diagnostic
- Prognostic
- Predictive
- Staging
- Surrogate endpoints
- Diagnostic Biomarkers
- function:
- diagnostic tool for identification of patients
with a disease or abnormal condition
- e.g. elevated blood glucose in individuals with diabetes mellitus
- widely used in diagnosis of cancer
- have the ability to determine the primary
tumour in cases where it has metastasised
- Prognostic Biomarkers
- Prognosis refers to the natural course of
the disease in the absence of treatment
- takes place after an individual has been
diagnosed with cancer
- Clinical example
- breast cancer
- better prognosis in patients that are ER+/PR+/HER+
- poor prognosis for cancers negative for these receptors
- Some cancers more aggressive than others
- biomarkers can help distinguish between
rapidly growing and slowly growing cancers
- patients can then receive different treatment
- patients with slowly growing tumours
may be spared aggressive treatments
- Predictive Biomarkers
- give an indication as to the
- likely response to treatment
- likelihood of developing a disease
- likelihood of disease recurrence
- clinical importance:
- some cancers that affect the same part of the body may
exhibit differences from person to person
- can influence how they respond to treatment
- EXAMPLE
- Human Epidermal Growth Factor Receptor 2 gene (HER2)
- 1/4 of breast cancer patients have a mutation in HER2 gene
- causes overexpression of HER2
- HER2+ breast cancers are likely to respond to
Trastuzimab, which inhibits HER2 protein activity
- HER2- patients will not respond to Trastuzimab
and so are not given this therapy
- HER2 overexpression causes breast cancers
to rapidly grow and divide
- aggressive cancer
- HER2 us a prognostic AND predictive biomarker
- OncotypeDX is used in early stage ER+ patients
who will be treated with hormone therapy
- evaluates a panel of 21 genes from a
tumour biopsy sample
- results in the form of a recurrence score indicating
the likelhood of tumour recurring in the next 10 years
- Staging Biomarkers
- used as a tool to classify the extent or stage of the disease
- Example
- CA-125 elevation in ovarian cancer
- PSA concentration in blood
- reflects extent of tumour growth and
metastasis in prostate cancer
- Surrogate endpoints
- clincal endpoint is a characteristic or variable that
reflects how a patient feels, functions or survives
- they are distinct measurements of disease characteristics
observed in a study that reflect the effect of therapeutic
intervention
- A surrogate endpoint is a biomarker that is intended
to substitute for a clinical endpoint
- it is expected to predict clinical benefit based on
epidaemiologic, therapeutic, pathophysiologic or other
scientific evidence
- EXAMPLE:
- effect of drug therapy on cancer progression and survival
- use of a validated surrogate endpoint would prevent patients
having to undergo tumour biopsies and trials to see if a drug
worked
- Instead, a blood test could be performed to determine whetehr the
biomarker has increased or decreased in response to the drug